| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S0140-6736(05)67601-5 |
| P698 | PubMed publication ID | 16243094 |
| P50 | author | George Davey Smith | Q21003878 |
| Shah Ebrahim | Q90615321 | ||
| Anna Hansell | Q61087747 | ||
| Lyle J. Palmer | Q30512610 | ||
| Sarah J Lewis | Q37613585 | ||
| P2093 | author name string | Paul R Burton | |
| P2860 | cites work | Commentary: Mendelian randomization--an update on its use to evaluate allogeneic stem cell transplantation in leukaemia | Q79904916 |
| Commentary: development of Mendelian randomization: from hypothesis test to 'Mendelian deconfounding' | Q79904933 | ||
| Lipid-related genes and myocardial infarction in 4685 cases and 3460 controls: discrepancies between genotype, blood lipid concentrations, and coronary disease risk | Q80346156 | ||
| Prenatal screening for cystic fibrosis: an early report card | Q80539134 | ||
| The family history--more important than ever | Q81059123 | ||
| ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease?* | Q22066036 | ||
| Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease | Q22337234 | ||
| How many diseases does it take to map a gene with SNPs? | Q22337263 | ||
| Searching for genetic determinants in the new millennium | Q22337300 | ||
| Scientific and ethical aspects of genetic screening of workers for cancer risk: The case of the n-acetyltransferase phenotype | Q24169682 | ||
| A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis | Q24310146 | ||
| Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies | Q24531993 | ||
| Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease | Q24550510 | ||
| The role of genetic polymorphisms in environmental health | Q24815139 | ||
| The International HapMap Project | Q27860695 | ||
| Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study | Q47658804 | ||
| Shattuck lecture--medical and societal consequences of the Human Genome Project. | Q48582472 | ||
| Long-term cognitive and emotional impact of genetic testing for carriers of cystic fibrosis: the effects of test result and gender. | Q50974548 | ||
| Incorrect recall of residual risk three years after carrier screening for cystic fibrosis: a comparison of two-step and couple screening. | Q51983120 | ||
| Epidemiology faces its limits. | Q52877590 | ||
| Genetically reduced antioxidative protection and increased ischemic heart disease risk: The Copenhagen City Heart Study. | Q55037941 | ||
| Apolipoprotein E isoforms, serum cholesterol, and cancer. | Q55060187 | ||
| Amount of DNA in plasma and cancer risk: A prospective study | Q57037855 | ||
| Association of C-Reactive Protein With Blood Pressure and Hypertension | Q57110219 | ||
| Commentary: The rough world of nutritional epidemiology: Does dietary fibre prevent large bowel cancer? | Q57128163 | ||
| Parameters for reliable results in genetic association studies in common disease | Q57240978 | ||
| Genome scans and candidate gene approaches in the study of common diseases and variable drug responses | Q57840862 | ||
| Pharmacogenetics of Inflammatory Bowel Disease | Q58037975 | ||
| The case for a US prospective cohort study of genes and environment | Q59051741 | ||
| CANALIZATION OF DEVELOPMENT AND THE INHERITANCE OF ACQUIRED CHARACTERS | Q59064935 | ||
| Can family history be used as a tool for public health and preventive medicine? | Q64127919 | ||
| Mendelian randomisation: a new spin or real progress? | Q64134143 | ||
| Lactase deficiency: prevalence in osteoporosis | Q67364196 | ||
| Does lactose intolerance predispose to low bone density? A population-based study of perimenopausal Finnish women | Q71589430 | ||
| Osteoporosis, Intestinal Lactase Deficiency and Low Dietary Calcium Intake | Q72344117 | ||
| Translating biomedical research to the bedside: a national crisis and a call to action | Q73116855 | ||
| Cystic fibrosis gene testing a challenge: experts say widespread use is creating unnecessary risks | Q73508822 | ||
| Population screening for cystic fibrosis: knowledge and emotional consequences 18 months later | Q73589507 | ||
| Population screening for cystic fibrosis in Western Australia: community response | Q74108588 | ||
| Pharmacogenetics | Q74843888 | ||
| Dissecting a population genome for targeted screening of disease mutations | Q77373277 | ||
| Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease | Q27860821 | ||
| Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study. European Prospective Investigation into Cancer and Nutrition | Q28204672 | ||
| ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer | Q28208394 | ||
| A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis | Q28267921 | ||
| Homocysteine and coronary heart disease in the Caerphilly cohort: a 10 year follow up | Q28345971 | ||
| The future of genetic studies of complex human diseases | Q29547215 | ||
| Replication validity of genetic association studies | Q29615456 | ||
| The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers | Q29616096 | ||
| Hypothesis: is low prenatal vitamin D a risk-modifying factor for schizophrenia? | Q33819585 | ||
| Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia | Q33891379 | ||
| Ryanodine receptor mutations in malignant hyperthermia and central core disease | Q33903152 | ||
| Case-control association studies for the genetics of complex respiratory diseases | Q33933058 | ||
| MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial | Q33960122 | ||
| Large upward bias in estimation of locus-specific effects from genomewide scans | Q34044873 | ||
| Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir | Q34117815 | ||
| Principles for the buffering of genetic variation | Q34171380 | ||
| Problems of reporting genetic associations with complex outcomes | Q34184173 | ||
| Association study designs for complex diseases | Q34186026 | ||
| Reflections on the limitations to epidemiology | Q34215778 | ||
| Pharmacogenetics: potential for individualized drug therapy through genetics | Q34273202 | ||
| Mendelian randomization: prospects, potentials, and limitations | Q34312296 | ||
| Vitamin E consumption and the risk of coronary heart disease in men. | Q34363912 | ||
| 1998 ASHG presidential address. Making genomic medicine a reality | Q34388472 | ||
| Experiences in molecular-based prenatal screening for Ashkenazi Jewish genetic diseases | Q34399100 | ||
| Epidemiological methods for studying genes and environmental factors in complex diseases | Q34421625 | ||
| Genetic hemochromatosis, a Celtic disease: is it now time for population screening? | Q34517626 | ||
| Finnish Disease Heritage I: characteristics, causes, background | Q34531986 | ||
| Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it? | Q34564801 | ||
| Strategies for early diagnosis of haemochromatosis | Q34601551 | ||
| Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence | Q34748119 | ||
| MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. | Q34974721 | ||
| Population screening in the age of genomic medicine | Q35037759 | ||
| An epidemiologic assessment of genomic profiling for measuring susceptibility to common diseases and targeting interventions | Q40537645 | ||
| Familial risk and genetic susceptibility for breast cancer | Q40654778 | ||
| Clustering of risk factors and social class in childhood and adulthood in British women's heart and health study: cross sectional analysis | Q40762277 | ||
| Psychological and social impact of carrier screening for cystic fibrosis among pregnant woman--a pilot study | Q40943638 | ||
| Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis | Q41161614 | ||
| Canalization: a molecular genetic perspective | Q41396336 | ||
| The new genetics in clinical practice | Q41728150 | ||
| Comparison of the genomic structure and variation in the two human sodium-dependent vitamin C transporters, SLC23A1 and SLC23A2. | Q42633800 | ||
| The effect of the C677T and A1298C polymorphisms in the methylenetetrahydrofolate reductase gene on homocysteine levels in elderly men and women from the British regional heart study | Q43546770 | ||
| Candidate-gene approaches for studying complex genetic traits: practical considerations | Q44636099 | ||
| Validity of self-report in alcoholism research: results of a Veterans Administration Cooperative Study | Q44774125 | ||
| Commentary: Katan's remarkable foresight: genes and causality 18 years on. | Q44838036 | ||
| Commentary: Mendelian randomization and gene-environment interaction | Q44838041 | ||
| Pharmacogenetic study of statin therapy and cholesterol reduction | Q44938097 | ||
| Using pharmacogenetics to improve drug safety and efficacy | Q44938100 | ||
| Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial | Q45121026 | ||
| Commentary: the concept of 'Mendelian Randomization'. | Q46041775 | ||
| Commentary: hormone replacement therapy and coronary heart disease: four lessons | Q46054104 | ||
| Laboratory standards and guidelines for population-based cystic fibrosis carrier screening | Q46673370 | ||
| Molecular genetic risk screening | Q35044209 | ||
| Genetic associations in large versus small studies: an empirical assessment | Q35070873 | ||
| Pharmacogenetics and personalised medicine | Q35071836 | ||
| Locating gene–environment interaction: at the intersections of genetics and public health | Q35116439 | ||
| Pharmacogenetics of Drug Metabolising Enzymes: Importance for Personalised Medicine | Q35127786 | ||
| N-Acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark | Q35133059 | ||
| The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones | Q35159851 | ||
| Genetic evaluation for coronary artery disease | Q35179025 | ||
| Genomic profiling to promote a healthy lifestyle: not ready for prime time | Q35201468 | ||
| Genomics as a probe for disease biology | Q35211343 | ||
| Risk and protective effects of the APOE gene towards Alzheimer's disease in the Kungsholmen project: variation by age and sex. | Q35481029 | ||
| Design, objectives, and lessons from a pilot 25 year follow up re-survey of survivors in the Whitehall study of London Civil Servants | Q35558356 | ||
| Genomic Priorities and Public Health | Q35566970 | ||
| Pharmacogenetics goes genomic | Q35590351 | ||
| Prenatal screening for cystic fibrosis: past, present and future | Q35623356 | ||
| Genetic testing for cardiovascular disease susceptibility: a useful clinical management tool or possible misinformation? | Q35625535 | ||
| Population genetic screening programmes: principles, techniques, practices, and policies | Q35626856 | ||
| The complex interplay among factors that influence allelic association. | Q35634519 | ||
| Fibrinogen, C-reactive protein and coronary heart disease: does Mendelian randomization suggest the associations are non-causal? | Q35672053 | ||
| Moving towards individualized medicine with pharmacogenomics | Q35784527 | ||
| The emergence of epidemiology in the genomics age. | Q35866648 | ||
| Hereditary cancer: guidelines in clinical practice. Breast and ovarian cancer genetics. | Q35914662 | ||
| Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management | Q35941950 | ||
| Neurodevelopment, neuroplasticity, and new genes for schizophrenia | Q35974517 | ||
| Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia | Q36047171 | ||
| What can mendelian randomisation tell us about modifiable behavioural and environmental exposures? | Q36119363 | ||
| Cancer prevention and diet: help from single nucleotide polymorphisms | Q36181606 | ||
| Alcohol, ALDH2, and esophageal cancer: a meta-analysis which illustrates the potentials and limitations of a Mendelian randomization approach | Q36231579 | ||
| Key concepts in genetic epidemiology | Q36254149 | ||
| Shaking the tree: mapping complex disease genes with linkage disequilibrium | Q36274243 | ||
| Estimating the survival benefits gained from providing national cancer genetic services to women with a family history of breast cancer. | Q36694081 | ||
| The APC variants I1307K and E1317Q are associated with colorectal tumors, but not always with a family history. | Q37484741 | ||
| P433 | issue | 9495 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | public health | Q189603 |
| P304 | page(s) | 1484-1498 | |
| P577 | publication date | 2005-10-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Genetic epidemiology and public health: hope, hype, and future prospects | |
| P478 | volume | 366 |
| Q38905976 | "The Google of Healthcare": enabling the privatization of genetic bio/databanking. |
| Q48555506 | 2006 Council Lecture: Lancelot to the rescue: realizing the promise of genomic medicine. |
| Q37155423 | 3. Risk Assessment |
| Q44657827 | A direct assessment of genetic contribution to the incidence of coronary infarct in the general population Greek EPIC cohort |
| Q30365147 | A gentle introduction to SNP analysis: resources and tools. |
| Q57263760 | A legal framework for biobanking: the German experience |
| Q35597343 | Abundant genetic overlap between blood lipids and immune-mediated diseases indicates shared molecular genetic mechanisms |
| Q43922635 | Adjusting for bias and unmeasured confounding in Mendelian randomization studies with binary responses |
| Q37657035 | Alcohol consumption and cognitive impairment in older men: a mendelian randomization study |
| Q29999760 | An Interactionist Perspective on Genetic and Environmental Contributions to Personality |
| Q91444729 | Assessing pleiotropy and mediation in genetic loci associated with chronic obstructive pulmonary disease |
| Q35801330 | Assessing the impact of nicotine dependence genes on the risk of facial clefts: An example of the use of national registry and biobank data. |
| Q36981790 | B-vitamins, genotype and disease causality |
| Q37083131 | Basis for korean genome study |
| Q33725581 | Being more realistic about the public health impact of genomic medicine |
| Q36916960 | Beta2-adrenoceptor polymorphisms and obstructive airway diseases: important issues of study design |
| Q58047301 | Beyond odds ratios — communicating disease risk based on genetic profiles |
| Q40181846 | Biobanking for epidemiological research and public health |
| Q26866132 | Biobanks and personalized medicine |
| Q26767428 | Biobanks in the era of personalized medicine: objectives, challenges, and innovation: Overview |
| Q56777634 | Biobanks need publicity |
| Q46833945 | C-reactive protein and its role in metabolic syndrome: mendelian randomisation study |
| Q35605244 | China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up |
| Q33314841 | Correction of population stratification in large multi-ethnic association studies |
| Q36006147 | Credible Mendelian randomization studies: approaches for evaluating the instrumental variable assumptions |
| Q41842055 | DNA: where to now? |
| Q36072265 | Demographic differences in willingness to provide broad and narrow consent for biobank research |
| Q47653917 | Depression is Associated with CRP SNPs in Patients with Family History |
| Q83880570 | Designs combining instrumental variables with case-control: estimating principal strata causal effects |
| Q33263590 | Dietetic guidelines on food and nutrition in the secondary prevention of cardiovascular disease - evidence from systematic reviews of randomized controlled trials (second update, January 2006). |
| Q36470922 | Differences in preferences for models of consent for biobanks between Black and White women. |
| Q92729186 | Dispositional negativity, cognition, and anxiety disorders: An integrative translational neuroscience framework |
| Q37598897 | Drug-induced liver injury: insights from genetic studies. |
| Q36497096 | EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions |
| Q45746397 | EpiHealth: a large population-based cohort study for investigation of gene-lifestyle interactions in the pathogenesis of common diseases |
| Q37244215 | Epidemiological study designs to investigate gene-behavior interactions in the context of human obesity |
| Q40235521 | Excessive alcohol consumption increases mortality in later life: a genetic analysis of the health in men cohort study |
| Q48080485 | Factors that influence characteristics of genetic biobanks |
| Q37993414 | Fetal programming: maternal nutrition and role of one-carbon metabolism. |
| Q24289225 | Fine mapping versus replication in whole-genome association studies |
| Q58707538 | Gene × Environment Interaction in Developmental Disorders: Where Do We Stand and What's Next? |
| Q37690765 | Gene-Environment Interactions in Preventive Medicine: Current Status and Expectations for the Future |
| Q56891358 | Genes Predisposing to Rapid Aneurysm Growth |
| Q36474994 | Genetic association studies in cancer: good, bad or no longer ugly? |
| Q93153600 | Genetic influences on treatment-seeking for common mental health problems in the UK biobank |
| Q39849131 | Genetic self knowledge and the future of epidemiologic confounding |
| Q36580332 | Genetic susceptibility to infectious diseases: big is beautiful, but will bigger be even better? |
| Q41880739 | Genetics of complex diseases |
| Q37800567 | Genetics of lung-cancer susceptibility |
| Q30914210 | Genome-wide scan for signatures of human population differentiation and their relationship with natural selection, functional pathways and diseases |
| Q41870892 | Geographic information systems and applied spatial statistics are efficient tools to study Hansen's disease (leprosy) and to determine areas of greater risk of disease. |
| Q90501364 | Higher Serum C Reactive Protein Determined C Reactive Protein Single-Nucleotide Polymorphisms Are Involved in Inherited Depression |
| Q28943532 | ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study |
| Q42850566 | Improving outcomes in pregnancy |
| Q30242031 | Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology |
| Q36710362 | Managing scientific uncertainty in health legislation. |
| Q29037397 | Mendelian Randomization for Strengthening Causal Inference in Observational Studies |
| Q21144649 | Mendelian randomisation and causal inference in observational epidemiology |
| Q38735373 | Mendelian randomisation in cardiovascular research: an introduction for clinicians |
| Q84187504 | Mendelian randomisation, triglycerides, and CHD |
| Q33825426 | Mendelian randomization analysis of case-control data using structural mean models |
| Q29391639 | Mendelian randomization as an instrumental variable approach to causal inference |
| Q37014218 | Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology? |
| Q35034381 | Mining the human phenome using allelic scores that index biological intermediates |
| Q37083115 | National Biobank of Korea: Quality control Programs of Collected-human Biospecimens |
| Q33890177 | National Biobanks: Clinical Labor, Risk Production, and the Creation of Biovalue |
| Q37611713 | Needs and Requirements of Modern Biobanks on the Example of Dystonia Syndromes |
| Q42357156 | New directions in childhood obesity research: how a comprehensive biorepository will allow better prediction of outcomes |
| Q28654959 | Newspaper coverage of biobanks |
| Q51630423 | On the use of multifactor dimensionality reduction (MDR) and classification and regression tree (CART) to identify haplotype-haplotype interactions in genetic studies. |
| Q92545993 | Polygenic risk scores outperform machine learning methods in predicting coronary artery disease status |
| Q37287988 | Polymorphisms of the CRP gene inhibit inflammatory response and increase susceptibility to depression: the Health in Men Study |
| Q37082500 | Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues |
| Q33646517 | Public health genomics and genetic test evaluation: the challenge of conducting behavioural research on the utility of lifestyle-genetic tests |
| Q36217664 | Public health in the genomic era: will Public Health Genomics contribute to major changes in the prevention of common diseases? |
| Q33683171 | Quality, quantity and harmony: the DataSHaPER approach to integrating data across bioclinical studies |
| Q34023951 | Rare association of turner syndrome with neurofibromatosis type 1 and tuberous sclerosis complex |
| Q28741456 | Realizing the promise of population biobanks: a new model for translation |
| Q33336256 | Reporting of human genome epidemiology (HuGE) association studies: an empirical assessment |
| Q28755468 | Size matters: just how big is BIG?: Quantifying realistic sample size requirements for human genome epidemiology |
| Q37390034 | Symposium on 'The challenge of translating nutrition research into public health nutrition'. Session 2: Personalised nutrition. Genetic variation and disease risk: new advances |
| Q80008226 | TNF gene polymorphism and quantitative traits related to cardiovascular disease: getting to the heart of the matter |
| Q37304154 | Testing for familial aggregation of functional traits |
| Q90290315 | Testosterone treatment in older men: clinical implications and unresolved questions from the Testosterone Trials |
| Q36032809 | The Diversity of Responsibility: The Value of Explication and Pluralization |
| Q26861372 | The Human Genome Project, and recent advances in personalized genomics |
| Q28750926 | The UK DNA banking network: a "fair access" biobank |
| Q36670492 | The balance between heritable and environmental aetiology of human disease |
| Q35677105 | The biobank of the Norwegian Mother and Child Cohort Study: a resource for the next 100 years |
| Q38735263 | The future of epidemiology: methods or matter? |
| Q36773933 | The future of genomic nursing research |
| Q42546573 | The genetics of age-related health outcomes |
| Q33456032 | The phenotype and genotype experiment object model (PaGE-OM): a robust data structure for information related to DNA variation |
| Q37218698 | The pressure of finding human hypertension genes: new tools, old dilemmas |
| Q43720473 | The triangular association of ADH1B genetic polymorphism, alcohol consumption and the risk of depression in older men. |
| Q36229441 | Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population |
| Q93192474 | Type-2 diabetes and risk of dementia: observational and Mendelian randomisation studies in 1 million individuals |
| Q89002017 | Using genetic data to strengthen causal inference in observational research |
| Q30839807 | Whole genome sequencing of one complex pedigree illustrates challenges with genomic medicine |
Search more.